Table 4

Clinical characteristics and plasma S100A12 levels in the validation population
All (n = 303) Died (n = 33)a Survived (n = 264)a P valueb
Age (years) 69.4 ± 11.7c 74.9 ± 10.5 68.7 ± 11.4 0.003**
Male/Female (n) 195/108 27/6 165/99 0.029*
Current smoker/nonsmoker (n) 51/252 5/28 46/218 0.744
Duration of HD (years) 7.4 ± 7.2 6.6 ± 4.4 7.6 ± 7.5 0.254
Systolic BP (mmHg) 148.3 ± 23.0 146.2 ± 26.7 148.5 ± 22.6 0.594
Hemoglobin (g/dL) 10.4 ± 1.2 9.9 ± 1.4 10.5 ± 1.2 0.007**
White blood cells (/mm3) 5438 ± 1579 5867 ± 1707 5393 ± 1557 0.104
Platelet (104/μL) 17.7 ± 5.8 16.8 ± 5.8 17.7 ± 5.8 0.380
hs-CRP (mg/L) 0.9 (0.4–3.4) d 1.4 (0.6–7.8) 0.9 (0.4–3.0) 0.013*
Creatinine (mg/dL) 9.0 ± 2.8 7.4 ± 2.6 9.3 ± 2.7 <0.001**
Albumin (g/dL) 3.6 ± 0.4 3.3 ± 0.5 3.6 ± 0.3 <0.001**
Sodium (mEq/L) 139.6 ± 2.8 138.8 ± 3.5 139.7 ± 2.6 0.172
Potassium (mEq/L) 4.9 ± 0.8 4.7 ± 0.8 4.9 ± 0.8 0.076
Adjusted calcium (mg/dL) 9.1 ± 0.7 9.2 ± 0.6 9.1 ± 0.7 0.404
Phosphate (mg/dL) 4.9 ± 1.2 4.6 ± 1.4 5.0 ± 1.2 0.162
Calcium (mg/dL) × Phosphate (mg/dL) 42.7 ± 11.5 39.5 ± 11.9 43.3 ± 11.5 0.078
Total cholesterol (mg/dL) 146.6 ± 34.3 142.6 ± 42.9 147.3 ± 32.7 0.453
DN/nonDN (n) 132/171 21/12 110/154 0.017*
History of CVD/no history of CVD (n) 86/217 15/18 69/195 0.020*
Plasma S100A12 levels (ng/mL) 20.39 (12.65–37.98)d 28.60 (14.18–43.80) 19.45 (12.54–35.46) 0.035*

aSix patients were excluded from the final evaluation because they moved to another dialysis center or were lost to follow-up. bDied versus survived. cMeans ± SD (all such values). dMedian value; 25%–75% value shown in parentheses (all such values). HD = hemodialysis, BP = blood pressure, hs-CRP = high-sensitivity C-reactive protein, DN = diabetic nephropathy, CVD = cardiovascular disease.

*P < 0.05, **P < 0.01.

Shiotsu et al.

Shiotsu et al. BMC Nephrology 2013 14:16   doi:10.1186/1471-2369-14-16

Open Data